Preclinical News and Research

RSS

FDA approves Novartis' Afinitor tablets for pancreatic NET treatment

Novartis Pharmaceuticals Corporation announced today that the US Food and Drug Administration approved Afinitor tablets for the treatment of progressive neuroendocrine tumors of pancreatic origin in patients with unresectable, locally advanced or metastatic disease.

6 May 2011

ArQule reports net loss of $1,466,000 for first quarter 2011

ArQule, Inc. today announced its financial results for the first quarter of 2011.

5 May 2011

The Miami Project, InVivo Therapeutics collaborate to develop novel spinal cord injury treatments

InVivo Therapeutics, a company focused on the development of groundbreaking technologies for the treatment of spinal cord injuries, and The University of Miami Miller School of Medicine's Miami Project to Cure Paralysis, the world's most comprehensive spinal cord injury research center, today announced a strategic research collaboration for the development of novel SCI treatments.

5 May 2011

Clinical study: Celecoxib drug may treat breast cancer

The anti-inflammatory drug celecoxib may be a useful additional treatment for people with breast cancer, Dutch researchers report at the IMPAKT Breast Cancer Conference in Brussels.

5 May 2011

Odyssey Thera receives US patent for application of contextual high-content assays to diverse biological events

Odyssey Thera, Inc. announced today that the United States Patent and Trademark Office granted U.S. Patent No. 7,935,493, entitled "Protein fragment complementation assays for high-throughput and high-content screening."

5 May 2011

TGen licenses ONCO-101 cancer drug to Syracuse

The Translational Genomics Research Institute has licensed its first drug, a unique compound that targets cancer tumors by modifying the actions of proteins.

5 May 2011

Selexys begins patient enrollment in SelG1 Phase I study for sickle cell disease

Selexys Pharmaceuticals announced today that it has initiated enrollment in a Phase I clinical study of its lead compound, SelG1, a humanized anti-P-selectin antibody.

5 May 2011

Affitech, Cancer Research Technology sign deal to advance therapeutic antibodies

Cancer Research Technology, the commercial arm of Cancer Research UK, has signed a license agreement to grant antibody medicines company, Affitech A/S, exclusive rights to a CRT patent application and relevant know how to develop and use therapeutic antibodies that recognise and block the function of CCR4, a protein found on certain tumours - including early and late stage cervical cancer and oesophageal cancer.

4 May 2011

Yale, Debiopharm partner to develop and commercialize Debio 1036 for inflammatory diseases

Debiopharm Group, a global biopharmaceutical development specialist that focuses on serious medical conditions and particularly oncology, and Yale University, a premier university with a long tradition of both basic and clinically directed biomedical research, announce an exclusive worldwide license agreement concerning the development and commercialization of Debio 1036, a first-in-class inhibitor for autoimmune and inflammatory diseases.

4 May 2011

New nano-vault delivery system can fight cancer

UCLA scientists have discovered a way to wake up the immune system to fight cancer by delivering an immune system-stimulating protein in a nanoscale container called a vault directly into lung cancer tumors, harnessing the body's natural defenses to fight disease growth.

4 May 2011

Esperion reports positive results from ETC-1002 Phase 1 study in dyslipidemia

Esperion Therapeutics, a privately held biotechnology company working to discover, develop and commercialize treatments for cardiovascular and metabolic diseases, today announced the results from a Phase 1 study and four preclinical studies for ETC-1002 at the Arteriosclerosis, Thrombosis and Vascular Biology 2011 Scientific Sessions in Chicago.

3 May 2011

New antioxidant may prevent liver damage in chronic alcoholics

An antioxidant may prevent damage to the liver caused by excessive alcohol, according to new research from the University of Alabama at Birmingham.

3 May 2011

Caliper first quarter revenue increases 25% to $35.8 million

Caliper Life Sciences, Inc., today reported its financial results for the first quarter of 2011. First quarter revenue increased to $35.8 million, or 25%, from $28.7 million in the same period of 2010.

2 May 2011

Temsirolimus with chemotherapy may serve as promising therapy for mesothelioma

A drug commonly used to treat kidney cancer may increase the effectiveness of chemotherapy for mesothelioma, according to a study published in the May issue of the Journal of Thoracic Oncology.

2 May 2011

Invivo Therapeutics' Chief Science Officer selected as recipient of 2011 Apple Award

InVivo Therapeutics, a company focused on the development of groundbreaking technologies for the treatment of spinal cord injuries, today announced that Chief Science Officer Dr. Christopher Pritchard, Ph.D., has been selected as the 2011 recipient of the American Spinal Injury Association's prestigious Apple Award.

30 Apr 2011

University of South Florida researcher earns Everfront Award for stem cell study

Dr. Paul Sanberg, Distinguished University Professor and senior associate vice president for research and innovation at the University of South Florida, received the Everfront Award at the 4th Pan Pacific Symposium on Stem Cell and Cancer Research held earlier this month in Taichung, Taiwan.

30 Apr 2011

ETP makes investment to support development of ICVrx's targeted epilepsy drug technology

Epilepsy Therapy Project, a non-profit organization whose mission is to accelerate new therapies for people living with epilepsy and seizures, and ICVrx, LLC, a pharmacy product research and development company focused on novel therapies for central nervous system disorders, announced today that ETP has made an investment in ICVrx to support the development of ICVrx's targeted epilepsy drug technology for patients whose seizures are not controlled by current therapies.

30 Apr 2011

Gene therapy approach using CD59 shows promise against AMD: Study

A gene therapy approach using a protein called CD59, or protectin, shows promise in slowing the signs of age-related macular degeneration, according to a new in vivo study by researchers at Tufts University School of Medicine.

30 Apr 2011

Journal Blood publishes MacroGenics' DART antibody technology preclinical data

MacroGenics, Inc., a privately held biotechnology company that develops immunotherapeutics to treat autoimmune disorders, cancer and infectious diseases, today announced the publication in the journal Blood of preclinical data demonstrating potent inhibition of B-cell lymphoma through redirected T lymphocyte-mediated killing, using its bispecific DART antibody technology.

29 Apr 2011

FDA accepts OncoMed's IND filing for OMP-18R5 in Phase 1 clinical trial for advanced solid tumors

OncoMed Pharmaceuticals, Inc., a company developing novel therapeutics that target cancer stem cells or tumor-initiating cells, today announced that the FDA has accepted an IND filing for OMP-18R5, which allows OncoMed to commence Phase 1 clinical testing.

28 Apr 2011

Preclinical News and Research

FDA approves Novartis' Afinitor tablets for pancreatic NET treatment

ArQule reports net loss of $1,466,000 for first quarter 2011

The Miami Project, InVivo Therapeutics collaborate to develop novel spinal cord injury treatments

Clinical study: Celecoxib drug may treat breast cancer

Odyssey Thera receives US patent for application of contextual high-content assays to diverse biological events

TGen licenses ONCO-101 cancer drug to Syracuse

Selexys begins patient enrollment in SelG1 Phase I study for sickle cell disease

Affitech, Cancer Research Technology sign deal to advance therapeutic antibodies

Yale, Debiopharm partner to develop and commercialize Debio 1036 for inflammatory diseases

New nano-vault delivery system can fight cancer

Esperion reports positive results from ETC-1002 Phase 1 study in dyslipidemia

New antioxidant may prevent liver damage in chronic alcoholics

Caliper first quarter revenue increases 25% to $35.8 million

Temsirolimus with chemotherapy may serve as promising therapy for mesothelioma

Invivo Therapeutics' Chief Science Officer selected as recipient of 2011 Apple Award

University of South Florida researcher earns Everfront Award for stem cell study

ETP makes investment to support development of ICVrx's targeted epilepsy drug technology

Gene therapy approach using CD59 shows promise against AMD: Study

Journal Blood publishes MacroGenics' DART antibody technology preclinical data

FDA accepts OncoMed's IND filing for OMP-18R5 in Phase 1 clinical trial for advanced solid tumors

Event guide: 4th LNP Formulation & Process Development Summit eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics